Lava Therapeutics reports Q2 EPS (31c) vs (48c) last year

“LAVA has continued to make progress in the Phase 1/2a study for LAVA-1207, our lead Gammabody product candidate in mCRPC. Patients in the Phase 1/2a study are being treated with LAVA-1207 monotherapy at dose level 12,” said Stephen Hurly, President and Chief Executive Officer of LAVA. “In Q2 2024, we initiated dosing in the pembrolizumab combination arm and have dosed our first patients. We expect to release the next data for LAVA-1207 at a medical meeting later this year. We are also excited to start our clinical trial for LAVA-1266 for AML/MDS later this year.”